$MRK Keytruda phase 3 study shows double the progression time (16.5 v 8.2 months) for untreated colon cancer w/MSI-H and dMMR mutations (both hinder (DNA repair) vs standard chemotherapy regiment. Another win for Keytruda #asco2020
C: StatNews ASCO In 30 Seconds newsletter May 31